DeltaWave TVMS is an investigational neuromodulation platform under clinical evaluation for its ability to support autonomic network regulation during sleep.

The system delivers ultra–low-intensity, non-contact, longitudinal transspinal subthreshold electromagnetic fields designed to influence distributed spinal–autonomic oscillatory dynamics without inducing direct neural depolarization.

This structured field exposure is intended to promote coordinated intersegmental timing across autonomic pathways, biasing physiologic conditions toward stable NREM3 slow-wave activity.

In early randomized clinical research, DeltaWave use has been associated with increased slow-wave sleep (SWS) duration and reduced SWS fragmentation — the sleep stage most closely linked to glymphatic clearance, synaptic homeostasis, and neuroendocrine restoration.

Clinical Study Validation
Slow-wave sleep (NREM3) was improved with DeltaWave TVMS Active device use relative to Sham, across three metrics:

➤ 36% increase in total minutes
➤ 42% increase in proportion of total sleep
➤ 72% decrease in disruptions per hour